Biotech Investing Cardiol Therapeutics' Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases 8h
Biotech Investing Cardiol Therapeutics Completes US$11.4 Million Financing and Extends Cash Runway into Q3 2027 21 October
